Association of UCP1 polymorphisms with type 2 diabetes mellitus and their interaction with physical activity and sedentary behavior-Reference-Cited by-同舟云学术

Association of UCP1 polymorphisms with type 2 diabetes mellitus and their interaction with physical activity and sedentary behavior

Published:2020-05 Issue: Volume:739 Page:144497
ISSN:0378-1119
Container-title:Gene
language:en
Short-container-title:Gene

Author:

Dong Chunting,Lv Yingnan,Xie Lianguang,Yang Rongqing,Chen Lulin,Zhang Lulu,Long Tianzhu,Yang Haisheng,Mao Xingning,Fan Qiuyu,Chen Xiaolang,Zhang Haiying

Funder

National Natural Science Foundation of China

Guangxi Natural Science Foundation

Publisher

Elsevier BV

Subject

Genetics,General Medicine

Reference38 articles.

1. Exercise-induced ‘browning’ of adipose tissues;Aldiss;Metab.-Clin. Exp.,2017

2. The on-off switches of the mitochondrial uncoupling proteins;Azzu;Trends Biochem. Sci.,2010

3. Physical training, UCP1 expression, mitochondrial density, and coupling in adipose tissue from women with obesity;Brandao;Scand. J. Med. Sci Sports,2019

4. The role of the uncoupling protein 1 (UCP1) on the development of obesity and type 2 diabetes mellitus;Brondani;Arq. Brasil. Endocrinol. Metabol.,2012

5. Comment on “obesity and the environment: where do we go from here?”;Butte;Science,2003

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decrease in UCP1 by sustained high lipid promotes NK cell necroptosis to exacerbate nonalcoholic liver fibrosis;Cell Death & Disease;2024-07-20

2. Genotypes of the UCP1 gene polymorphisms and cardiometabolic diseases: A multifactorial study of association with disease probability;Biochimie;2024-03

3. Decrease in UCP1 by sustained high lipid promotes NK cell necroptosis to exacerbate nonalcoholic liver fibrosis;2023-10-16

4. Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms;Nutrients;2023-05-24

5. Protein Uncoupling as an Innovative Practice in Diabetes Mellitus Treatment: A Metabolic Disorder;Endocrine, Metabolic & Immune Disorders - Drug Targets;2023-04